|
Professor of Pharmacology
Director, Department of Biomedical Sciences and
Biotechnologies, University of Brescia Medical School, Brescia, Italy
Education.
1977 Graduated in Chemistry and Pharmaceutical
Technology at the University of Cagliari, Italy
1980 Residency
in Pharmacology, University of Milan, Milan, Italy
Position
and employment. 1980-1982
Research fellow, at the National Heart, Lung and Blood Institute, Section on
Biochemical Pharmacology, National Institute of Health, Bethesda, MD, USA.
1983-1988 Researcher of Pharmacology, at the University of Cagliari,
Italy. 1988-1990 Visiting Associate Professor of Pharmacology,
Georgetown University Medical School, Washington D.C., USA. 1988-2000
Associate Professor of Pharmacology, at the University of Brescia, Italy.
2000- present Full Professor of Pharmacology, at the University of
Brescia, Italy.
Other Experience and Professional Membership.
1980- Member Society of Italian Pharmacology (SIF). 1985- Member, American
Society of Neuroscience. 1988-2000 Professor Neuropsycopharmacology,
University of Brescia, Italy. 1990- Member Society of Italian Neuroscience
(SIN). 1991- Founder and President of the Italian Group of Molecular
Neurobiology. 1994- Professor Faculty PhD program in Neuroscience. 1995-
Founder and Vice-President of the European School of Molecular Medicine.
1996- Professor Faculty Residency in Pharmacology. 1998- Associate Editor
of "Functional Neurology" . 2000- Chief Molecular Neuropharmacology
Laboratory, University of Brescia, Italy. 2000- Full Professor of
Pharmacology, University of Brescia Medical School. 2002 Owner of a patent
entitled "Useful compound for the treatment of neurodegenerative disease".
2003 Owner of a patent entitled "Method for early identification of
Alzheimer's Disease". 2005 Member of the Editorial Board of
"CNS Drug
Review". 2007 Associated Editor of
"BMC Pharmacology"
Current research interests:
Neuropharmacology,
role of Dopamine systems in schizophrenia and Parkinson's disease, molecular
mechanisms of neurodegeneration, genetic and molecular risk factors for
Alzheimer's disease; molecular mechanisms associated with neuroblastoma
growth.
Description of the main domain of
research:
-
Identification and
characterization of different DA receptor subtypes (named D1 and D2) in
CNS and periphery (1978-1988)
-
Characterization of DA receptor
function in schizophrenic brain (1980-1983)
-
Characterization of the
transcriptional activity induced by glutamate receptor stimulation
(1988-1991)
-
Characterization of the
physiopathological role of the NF-kappaB pathway in the CNS (1993-present
-
Discovery of neuroprotective
activity of Aspirin and other anti-inflammatory drugs (1995-1998)
-
Identification of p53 as a
novel participant in neurodegenerative process (1997-present)
-
Characterization of the
physiopathological role of DNA damage repair systems in neurodegenerative
diseases (1998-2008)
-
Identification of p53 as a
possible biomarker for Alzheimer disease (2000-present)
|
